Avalo Therapeutics AVTX Accrued Royalties (Current)
Accrued Royalties (Current) at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccruedRoyaltiesCurrent.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's accrued royalties (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's accrued royalties (current)?
- Avalo Therapeutics (AVTX) reported accrued royalties (current) of $327K in Q1 2026.
- How has Avalo Therapeutics's accrued royalties (current) changed year-over-year?
- Avalo Therapeutics's accrued royalties (current) decreased by 0.0% year-over-year, from $327K to $327K.
- What is the long-term trend for Avalo Therapeutics's accrued royalties (current)?
- Over 5 years (2020 to 2025), Avalo Therapeutics's accrued royalties (current) has grown at a -30.4% compound annual growth rate (CAGR), from $2M to $327K.
- What does accrued royalties (current) mean?
- This represents the short-term financial obligation for royalty payments incurred based on licensing agreements or intellectual property usage that remain unpaid at the balance sheet date. It serves as a measure of the company's near-term cash commitments related to its licensed technology and pipeline assets. Tracking this liability provides insight into the cost structure associated with external innovation and the timing of cash outflows for contractual obligations.